L3VLUP
ProSign in

ONC · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

ONCLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • ONC
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterONCLLY
Q3 20205 holders, $2.9bn33 holders, $14.1bn
Q4 20209 holders, $2.9bn29 holders, $17.3bn
Q1 20219 holders, $4.7bn24 holders, $23.0bn
Q2 20219 holders, $4.2bn24 holders, $27.8bn
Q3 20216 holders, $4.4bn31 holders, $29.9bn
Q4 20216 holders, $3.2bn31 holders, $34.7bn
Q1 20224 holders, $2.0bn24 holders, $35.3bn
Q2 20224 holders, $1.5bn33 holders, $42.7bn
Q3 20225 holders, $1.2bn31 holders, $43.4bn
Q4 20226 holders, $2.1bn31 holders, $46.6bn
Q1 20237 holders, $1.8bn33 holders, $44.3bn
Q2 20236 holders, $1.5bn37 holders, $59.6bn
Q3 20234 holders, $1.7bn44 holders, $67.6bn
Q4 20232 holders, $1.0bn45 holders, $73.6bn
Q1 20244 holders, $926m41 holders, $95.3bn
Q2 20247 holders, $949m43 holders, $110bn
Q3 20247 holders, $1.6bn45 holders, $107bn
Q4 20244 holders, $1.3bn46 holders, $93.9bn
Q1 202514 holders, $3.4bn42 holders, $98.4bn
Q2 20256 holders, $1.3bn43 holders, $93.2bn
Q3 20258 holders, $2.1bn39 holders, $86.7bn
Q4 20259 holders, $1.8bn41 holders, $123bn
Q1 20269 holders, $2.1bn39 holders, $106bn
Q2 202612 holders, $2.5bn44 holders, $132bn
ONC

Beone Medicines LTD

Holders
12
Reported value
$2.5bn
Buyers
16
Sellers
12

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
44
Reported value
$132bn
Buyers
24
Sellers
24

Breadth 0 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 45 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only ONC (1)

Baillie Gifford & Co

Only LLY (33)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, ARK Investment Management LLC, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, D. E. Shaw & Co., Discovery Capital Management LLC, Dodge & Cox, ExodusPoint Capital Management LP, Freestone Grove Partners LP, GAMCO Investors Inc, Glenview Capital Management LLC, Harris Associates LP, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, MFS Investment Management, Neuberger Berman Group LLC, Polen Capital Management LLC, Quantbot Technologies LP, and 8 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →